Statins in Portal Hypertension
Juan G Abraldes MD
Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorVincenzo La Mura MD
Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorJaime Bosch MD
Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain
Search for more papers by this authorJuan G Abraldes MD
Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorVincenzo La Mura MD
Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorJaime Bosch MD
Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain
Search for more papers by this authorRoberto de Franchis MD, AGAF
Professor of Gastroenterology Head
Department of Medical Sciences, University of Milan, and Gastroenterology 3 Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Mangiagalli and Regina Elena Foundation, Milan, Italy
Search for more papers by this authorSummary
This chapter contains sections titled:
-
The need for new drugs in portal hypertension
-
Rationale for the use of statins in cirrhosis
-
Statins in patients with cirrhosis
-
Other potential benefits of statins in cirrhosis
-
Future perspectives
-
References
References
- Groszmann RJ, Abraldes JG (2005) Portal hypertension: from bedside to bench. J Clin Gastroenterol 39: S125–30.
- Bosch J, Berzigotti A, García-Pagán JC, et al. (2008) The management of portal hypertension: rational basis, available treatments and future options. JHepatol 48 (Suppl 1): S68–92.
- Bosch J, Abraldes JG, Groszmann RJ (2003) Current management of portal hypertension. JHepatol 38: S54–68.
- Failli P, De Franco RM, Caligiuri A, et al. (2000) Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology 119: 479–92.
- Yu Q, Shao R, Qian HS, et al. (2000) Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 105: 741–8.
- Van de Casteele M, Omasta A, Janssens S, et al. (2002) In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 51: 440–5.
- Morales-Ruiz M, Cejudo-Martin P, Fernandez-Varo G, et al. (2003) Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 125: 522–31.
- Dangas G, Smith DA, Unger AH, et al. (2000) Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 83: 688–92.
- Lefer DJ (2002) Statins as potent anti-inflammatory drugs. Circulation 106: 2041–2.
- Kureishi Y, Luo Z, Shiojima I, et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004–10.
- Bates K, Ruggeroli CE, Goldman S, et al. (2002) Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol 283: H768–75.
- Laufs U, Gertz K, Dirnagl U, et al. (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942: 23–30.
- Kalinowski L, Dobrucki LW, Brovkovych V, et al. (2002) Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105; 933–8.
- Fulton D, Gratton JP, McCabe TJ, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase. Akt Nature 399: 597–601.
- Laufs U, La FV, Plutzky J, et al. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129–35.
- Zafra C, Abraldes JG, Turnes J, et al. (2004) Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126: 749–55.
- Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, et al. (2007) Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. JHepatol 46: 1040–6.
- Trebicka J, Hennenberg M, Laleman W, et al. (2007) Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46: 242–53.
- Trebicka J, Hennenberg M, Odenthal M, et al. (2010) Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53: 702–12.
- Abraldes JG, Albillos A, Bañares R, et al. (2009) Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136: 1651–8.
- Mastai R, Bosch J, Navasa M, et al. (1987) Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. JHepatol 4: 71–9.
- Ritzel U, Leonhardt U, Nather M, et al. (2002) Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 36: 454–8.
- Chalasani N (2005) Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41: 690–5.
- Vuppalanchi R, Teal E, Chalasani N (2005) Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 329: 62–5.
- Khorashadi S, Hasson NK, Cheung RC (2006) Incidence of statin hepatotoxi-city in patients with hepatitis C. Clin Gastroenterol Hepatol 4: 902–7.
- Stojakovic T, Putz-Bankuti C, Fauler G, et al. (2007) Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46: 776–84.
- Browning JD (2006) Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 44: 466–71.
- Lewis JH, Mortensen ME, Zweig S, et al. (2007) Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46: 1453–63.
- O'Leary JG, Chan JL, McMahon CM, et al. (2007) Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 45: 895–8.
- Argo CK, Loria P, Caldwell SH, et al. (2008) Statins in liver disease: A molehill, an iceberg, or neither?; Hepatology 48: 662–9.
- Moreno M, Ramalho LN, Sancho-Bru P, et al. (2009) Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 296: G147–56.
- Glynn RJ, Danielson E, Fonseca FA, et al. (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360: 1851–61.
- Francoz C, Belghiti J, Vilgrain V, et al. (2005) Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 54: 691–7.
- Zocco MA, Di Stasio E, De Christofaro R, et al. (2009) Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. JHepatol 51: 682–9.
- Janda S, Young A, Fitzgerald JM, et al. (2010) The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-analysis. J Crit Care 2010, Apr 21 [Epub ahead print].
- Gao F, Linhartova L, Johnston AM, et al. (2008) Statins and sepsis. Br J Anaesth 100: 288–98.
- García-Pagán JC, Villanueva C, Albillos A, et al. (2009) Nadolol plus isosor-bide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 58: 1144–50.
- Feron O, Dessy C, Desager JP, et al. (2001) Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103: 113–18.
- Hattori Y, Nakanishi N, Akimoto K, et al. (2003) HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23: 176–82.
